A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 160-163

  Aravantinos, G ^a   Skarlos, D V ^a   Kosmidis, P ^c   Athanassiades, A ^b   Bafaloukos, D ^c   Giannakakis, T ^a   Karpathios, S ^d   Fountzilas, G ^b  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c METAXA Cancer Memorial Hospital   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

Author keywords

ovarian cancer chemotherapy; paclitaxel chemotherapy

Indexed keywords

PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT COMPLIANCE; PLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031036013     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00366-8     Document Type: Article

References (15)

1. 1. Gore ME, Wiltshaw FE, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynaecol Oncol 1990, 36, 207-211.
2. 2. McGuire WP, Rowinsky EK. Old drugs revisited, new drugs and experimental approaches in ovarian cancer therapy. Semin Oncol 1991, 18, 255-269.
3. 3. Williams CJ, Stewart L, Parmar M, Guthrie D (Advanced Ovarian Cancer Trialist Group). Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. Semin Oncol 1992, 19 (1, Suppl. 2), 120-128.
4. 4. Einzing AI, Wiernik PH, Sasloff J, et al. Phase II study and long term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992, 10, 1748-1753.
5. 5. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985, 53, 229-232.
6. 6. Mantel N. Evaluation of survival data and the two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50, 163-170.
7. 7. Breslow NA. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 1970, 57, 579-594.
8. 8. Tarone R, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977, 64, 156-160.
9. 9. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972, 34, 187-220.
10. 10. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111, 273-279.
11. 11. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994, 12, 1748-1753.
12. 12. Kohn EC, Sarosy G, Bicher A, et al. Dose intense taxol: high response rate in patients with platinum resistant recurrent ovarian cancer. J Natl Cancer Inst 1994, 86, 18-24.
13. 13. Trimble EL, Adams JD, Vene D, et al. Paclitaxel for the platinum refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993, 11, 2405-2410.
14. 14. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of taxol in relapsed ovarian cancer: high vs low dose and long vs short infusion. J Clin Oncol 1994, 12, 2654-2666.
15. 15. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334, 1-6.